The global vulvovaginal candidiasis treatment market is currently valued at USD 1035 million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in healthcare ...

Mundipharma has announced that rezafungin is now available in the Republic of Ireland for adult patients with invasive ...

The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients ...

Yeast infections can happen again and again which is why the initial infection should be treated properly An expert shares ...

Thrush and bacterial vaginosis (BV) are common vaginal infections that can cause symptoms including abnormal discharge. They are also both easily treatable, but Deborah Bateson says because there is ...

Also known as cutaneous candidiasis, a yeast infection of the ... This can include inspecting the feet regularly and receiving prompt treatment for any signs of an infection.

New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) </ ...

Systemic fungal infections like invasive candidiasis in ICU patients or those ... Resistance to standard drugs makes treatment longer and more expensive, especially in patients with compromised ...

Globally, recurrent vulvovaginal candidiasis, or recurrent yeast infections ... Your doctor can investigate the root cause and provide effective treatment and lifestyle counselling to prevent ...

Most patients (91/98, 92.9%) had candidemia, and 7/98 (7.1%) patients had other forms of invasive candidiasis. Treatment success was observed for 35/48 (72.9%) patients treated with micafungin and ...